Xponance, Inc. Viking Therapeutics, Inc. Transaction History
Xponance, Inc.
- $10.7 Billion
- Q4 2024
A detailed history of Xponance, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 14,024 shares of VKTX stock, worth $427,451. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,024
Previous 13,414
4.55%
Holding current value
$427,451
Previous $849,000
33.57%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VKTX
# of Institutions
471Shares Held
66.4MCall Options Held
5.88MPut Options Held
3.83M-
Vanguard Group Inc Valley Forge, PA10.2MShares$310 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$184 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$150 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$79.1 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$65.8 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.34B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...